申请人:BASF Aktiengesellschaft
公开号:US04921960A1
公开(公告)日:1990-05-01
The new compounds of the general Formula I ##STR1## (wherein R.sub.1 stands for C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkinyl, C.sub.3-7 cycloalkyl or optionally substituted phenyl-(C.sub.1-4 alkyl); R.sub.2 represents hydrogen or C.sub.1-5 alkanoyl; X.sub.1 and X.sub.2 can be identical or different and each stands for hydrogen, halogen, trifluoromethyl or C.sub.1-4 alkoxy; (with the proviso that if R.sub.1 stands for ethyl, at least one of R.sub.2, X.sub.1 and X.sub.2 is different from hydrogen) and pharmaceutically acceptable acid additions salts possess valuable anxiolytic properties devoid of sedative effect and can be used in therapy. The compounds of the general Formula I can be prepared by methods known per se.
通用式I的新化合物##STR1##(其中R.sub.1代表C.sub.1-5烷基,C.sub.2-5烯基,C.sub.2-5炔基,C.sub.3-7环烷基或可选择取代的苯基-(C.sub.1-4烷基);R.sub.2代表氢或C.sub.1-5烷酰基;X.sub.1和X.sub.2可以相同或不同,每个代表氢,卤素,三氟甲基或C.sub.1-4烷氧基;(但如果R.sub.1代表乙基,则R.sub.2,X.sub.1和X.sub.2中至少有一个与氢不同)并且药学上可接受的酸盐具有有价值的抗焦虑性能而无镇静作用,可用于治疗。通用式I的化合物可以通过已知的方法制备。